初级保健机构酒精使用障碍综合药物治疗:范围综述

IF 3.7 2区 医学 Q1 PSYCHOLOGY, CLINICAL Journal of Substance Abuse Treatment Pub Date : 2023-01-01 DOI:10.1016/j.jsat.2022.108919
Colby J. Hyland , Michal J. McDowell , Paul A. Bain , Haiden A. Huskamp , Alisa B. Busch
{"title":"初级保健机构酒精使用障碍综合药物治疗:范围综述","authors":"Colby J. Hyland ,&nbsp;Michal J. McDowell ,&nbsp;Paul A. Bain ,&nbsp;Haiden A. Huskamp ,&nbsp;Alisa B. Busch","doi":"10.1016/j.jsat.2022.108919","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Alcohol use disorder (AUD) represents the most prevalent addiction in the United States. Integration of AUD treatment in primary care settings would expand care access. The objective of this </span>scoping review<span> is to examine models of AUD treatment in primary care that include pharmacotherapy (acamprosate, disulfiram, naltrexone).</span></p></div><div><h3>Methods</h3><p>The team undertook a search across MEDLINE, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, and Web of Science on May 21, 2021. Eligibility criteria included: patient population ≥ 18 years old, primary care-based setting, US-based study, presence of an intervention to promote AUD treatment, and prescription of FDA-approved AUD pharmacotherapy. Study design was limited to controlled trials and observational studies. We assessed study bias using a modified Oxford Centre for Evidence-based Medicine Rating Framework quality rating scheme.</p></div><div><h3>Results</h3><p>The qualitative synthesis included forty-seven papers, representing 25 primary studies. Primary study sample sizes ranged from 24 to 830,825 participants and many (44 %) were randomized controlled trials<span><span>. Most studies (80 %) included a nonpharmacologic intervention for AUD: 56 % with brief intervention, 40 % with motivational interviewing, and 12 % with motivational enhancement therapy. A plurality of studies (48 %) included mixed pharmacologic interventions, with administration of any combination of naltrexone, </span>acamprosate, and/or disulfiram. Of the 47 total studies included, 68 % assessed care initiation and engagement. Fewer studies (15 %) explored practices surrounding screening for or diagnosing AUD. Outcome measures included receipt of pharmacotherapy and alcohol consumption, which about half of studies included (53 % and 51 %, respectively). Many of these outcomes showed significant findings in favor of integrated care models for AUD.</span></p></div><div><h3>Conclusions</h3><p>The integration of AUD pharmacotherapy in primary care settings may be associated with improved process and outcome measures of care. Future research should seek to understand the varied experiences across care integration models.</p></div>","PeriodicalId":17148,"journal":{"name":"Journal of Substance Abuse Treatment","volume":"144 ","pages":"Article 108919"},"PeriodicalIF":3.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321472/pdf/","citationCount":"1","resultStr":"{\"title\":\"Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review\",\"authors\":\"Colby J. Hyland ,&nbsp;Michal J. McDowell ,&nbsp;Paul A. Bain ,&nbsp;Haiden A. Huskamp ,&nbsp;Alisa B. Busch\",\"doi\":\"10.1016/j.jsat.2022.108919\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Alcohol use disorder (AUD) represents the most prevalent addiction in the United States. Integration of AUD treatment in primary care settings would expand care access. The objective of this </span>scoping review<span> is to examine models of AUD treatment in primary care that include pharmacotherapy (acamprosate, disulfiram, naltrexone).</span></p></div><div><h3>Methods</h3><p>The team undertook a search across MEDLINE, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, and Web of Science on May 21, 2021. Eligibility criteria included: patient population ≥ 18 years old, primary care-based setting, US-based study, presence of an intervention to promote AUD treatment, and prescription of FDA-approved AUD pharmacotherapy. Study design was limited to controlled trials and observational studies. We assessed study bias using a modified Oxford Centre for Evidence-based Medicine Rating Framework quality rating scheme.</p></div><div><h3>Results</h3><p>The qualitative synthesis included forty-seven papers, representing 25 primary studies. Primary study sample sizes ranged from 24 to 830,825 participants and many (44 %) were randomized controlled trials<span><span>. Most studies (80 %) included a nonpharmacologic intervention for AUD: 56 % with brief intervention, 40 % with motivational interviewing, and 12 % with motivational enhancement therapy. A plurality of studies (48 %) included mixed pharmacologic interventions, with administration of any combination of naltrexone, </span>acamprosate, and/or disulfiram. Of the 47 total studies included, 68 % assessed care initiation and engagement. Fewer studies (15 %) explored practices surrounding screening for or diagnosing AUD. Outcome measures included receipt of pharmacotherapy and alcohol consumption, which about half of studies included (53 % and 51 %, respectively). Many of these outcomes showed significant findings in favor of integrated care models for AUD.</span></p></div><div><h3>Conclusions</h3><p>The integration of AUD pharmacotherapy in primary care settings may be associated with improved process and outcome measures of care. Future research should seek to understand the varied experiences across care integration models.</p></div>\",\"PeriodicalId\":17148,\"journal\":{\"name\":\"Journal of Substance Abuse Treatment\",\"volume\":\"144 \",\"pages\":\"Article 108919\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321472/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Substance Abuse Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S074054722200201X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHOLOGY, CLINICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Substance Abuse Treatment","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S074054722200201X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 1

摘要

背景:酒精使用障碍(AUD)是美国最普遍的成瘾症。在初级保健机构整合AUD治疗将扩大护理可及性。本综述的目的是检查包括药物治疗(阿坎普罗酸、双硫仑、纳曲酮)在内的初级保健中的AUD治疗模式。研究小组于2021年5月21日在MEDLINE、PsycINFO、CINAHL、Cochrane Central Register of Controlled Trials和Web of Science上进行了检索。入选标准包括:患者年龄≥18岁,以初级保健为基础的环境,美国研究,存在促进AUD治疗的干预措施,以及fda批准的AUD药物治疗处方。研究设计仅限于对照试验和观察性研究。我们使用改良的牛津循证医学评价框架质量评价方案来评估研究偏倚。结果定性综合纳入论文47篇,主要研究25篇。主要研究样本量从24到830,825名参与者不等,其中许多(44%)是随机对照试验。大多数研究(80%)包括AUD的非药物干预:56%的短期干预,40%的动机访谈,12%的动机增强治疗。多项研究(48%)包括混合药物干预,使用纳曲酮、阿坎普罗酸和/或双硫仑的任何组合。在纳入的总共47项研究中,68%评估了护理的开始和参与。较少的研究(15%)探讨了围绕筛查或诊断AUD的实践。结果测量包括接受药物治疗和饮酒,约有一半的研究包括(分别为53%和51%)。许多这些结果显示了支持AUD综合护理模式的重要发现。结论:在初级保健机构中整合AUD药物治疗可能与改善护理过程和结果措施有关。未来的研究应寻求了解不同的护理整合模式的经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review

Background

Alcohol use disorder (AUD) represents the most prevalent addiction in the United States. Integration of AUD treatment in primary care settings would expand care access. The objective of this scoping review is to examine models of AUD treatment in primary care that include pharmacotherapy (acamprosate, disulfiram, naltrexone).

Methods

The team undertook a search across MEDLINE, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, and Web of Science on May 21, 2021. Eligibility criteria included: patient population ≥ 18 years old, primary care-based setting, US-based study, presence of an intervention to promote AUD treatment, and prescription of FDA-approved AUD pharmacotherapy. Study design was limited to controlled trials and observational studies. We assessed study bias using a modified Oxford Centre for Evidence-based Medicine Rating Framework quality rating scheme.

Results

The qualitative synthesis included forty-seven papers, representing 25 primary studies. Primary study sample sizes ranged from 24 to 830,825 participants and many (44 %) were randomized controlled trials. Most studies (80 %) included a nonpharmacologic intervention for AUD: 56 % with brief intervention, 40 % with motivational interviewing, and 12 % with motivational enhancement therapy. A plurality of studies (48 %) included mixed pharmacologic interventions, with administration of any combination of naltrexone, acamprosate, and/or disulfiram. Of the 47 total studies included, 68 % assessed care initiation and engagement. Fewer studies (15 %) explored practices surrounding screening for or diagnosing AUD. Outcome measures included receipt of pharmacotherapy and alcohol consumption, which about half of studies included (53 % and 51 %, respectively). Many of these outcomes showed significant findings in favor of integrated care models for AUD.

Conclusions

The integration of AUD pharmacotherapy in primary care settings may be associated with improved process and outcome measures of care. Future research should seek to understand the varied experiences across care integration models.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.60
自引率
10.30%
发文量
220
期刊介绍: The Journal of Substance Abuse Treatment (JSAT) features original reviews, training and educational articles, special commentary, and especially research articles that are meaningful to the treatment of alcohol, heroin, marijuana, and other drugs of dependence. JSAT is directed toward treatment practitioners from all disciplines (medicine, nursing, social work, psychology, and counseling) in both private and public sectors, including those involved in schools, health centers, community agencies, correctional facilities, and individual practices. The editors emphasize that JSAT articles should address techniques and treatment approaches that can be used directly by contemporary practitioners.
期刊最新文献
Not in my treatment center: Leadership's perception of barriers to MOUD adoption Peer support to reduce readmission in Medicaid-enrolled adults with substance use disorder National trends in buprenorphine prescribing before and during the COVID-19 pandemic A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations An intervention pilot to facilitate harm reduction service decentralization in Vietnam
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1